<DOC>
	<DOCNO>NCT01467141</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial evaluate safety efficacy child type 1 diabetes .</brief_summary>
	<brief_title>Safety Efficacy Insulin Aspart Children With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Type 1 diabetes Treatment insulin least 6 month prior inclusion HbA1c equal 11.0 % Currently treat short acting , intermediate acting , long act human insulin analogue selfmix insulin least 1 month prior inclusion The receipt investigational drug within one month prior trial Recurrent severe hypoglycaemia hypoglycaemic awareness judge investigator Total daily insulin dos least 1.80 IU/kg Treatment oral hypoglycaemic agent Known suspect allergy trial product relate product</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>